4
Views
0
CrossRef citations to date
0
Altmetric
CNS Agents

Patent Evaluation: CNS Azole-Alkyl-Piperidine Analogues of the Azapirones

Pages 1881-1882 | Published online: 02 Mar 2011
 

Summary

Novelty: 1,4-Disubstituted piperazines are claimed as novel treatments for anxiety, depression, and similar CNS disorders, as well as hypertension.

Biology: In vivo anxiolytic activity was tested using a conditioned avoidance response paradigm. The preferred compounds, 1 and 2, have oral ED50's of 6.1 and 6.3 mg/kg, respectively, compared to 17.2 and 26.1 for buspirone and ipsapirone, respectively. The preferred compound 3, unlike buspirone and ipsapirone, demonstrated anxiolytic activity in an addiction (to diazepam, alcohol, cocaine and nicotine) withdrawal paradigm (Costall et al. J. Pharm. Pharmacol. (1988) 40:494-500). The method of Janssen et al. (Arzheim. Forsch. (1963) 13:205) was used to test the ability of these compounds to antagonize the hypertensive effects of noradrenaline. The preferred compound 4, at dose of 0.18 mg/kg ip, protected 50% of the rats from death by hypertensive crisis induced by the iv injection of noradrenaline.

Chemistry: Examples of nine standard syntheses of the compounds are given. Forty-five compounds are specifically claimed and characterized by mp, IR and NMR. The specified compound is 1-[4-[4[(2-pyrimidinyl)-1-piperazinyl]butyl]-1 H-benzimidazole (1).

Structure:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.